(RELX) Relx - Overview
Exchange: NYSE •
Country: United Kingdom •
Currency: USD •
Type: Common Stock •
ISIN: US7595301083
Stock: Information, Analytics, Data, Tools, Software
Total Rating 39
Risk 74
Buy Signal -0.83
| Risk 5d forecast | |
|---|---|
| Volatility | 24.4% |
| Relative Tail Risk | 2.35% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.92 |
| Alpha | -37.15 |
| Character TTM | |
|---|---|
| Beta | 0.496 |
| Beta Downside | 0.320 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.91% |
| CAGR/Max DD | 0.13 |
Description: RELX Relx March 05, 2026
RELX PLC provides information-based analytics and decision tools across four segments: Risk, Scientific, Technical & Medical, Legal, and Exhibitions. This business model is common in the information services sector, which typically involves high intellectual property value and recurring revenue streams.
The Risk segment focuses on analytics for risk evaluation and prediction, including commercial healthcare. The Scientific, Technical & Medical segment supplies scientific and medical information and datasets. The Legal segment provides legal, regulatory, and business information and analytics, a core component of legal tech. The Exhibitions segment facilitates connections and transactions through digital tools and in-person events, a strategy increasingly adopted by event organizers to enhance engagement.
RELX PLC was incorporated in 1903 and is headquartered in London, United Kingdom. To learn more about RELX PLCs financial performance and market position, consider exploring its detailed reports on ValueRay.
Headlines to watch out for
- Subscription revenue growth in analytics tools
- Data and content acquisition costs impact margins
- Regulatory scrutiny on data privacy increases compliance burden
- Global economic slowdown reduces exhibition attendance
- Healthcare and legal sector demand drives analytics tool adoption
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 3.99b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.37 > 0.02 and ΔFCF/TA 16.54 > 1.0 |
| NWC/Revenue: -15.94% < 20% (prev -18.93%; Δ 2.99% < -1%) |
| CFO/TA 0.37 > 3% & CFO 5.51b > Net Income 3.99b |
| Net Debt (7.19b) to EBITDA (6.07b): 1.18 < 3 |
| Current Ratio: 0.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.83b) vs 12m ago -3.31% < -2% |
| Gross Margin: 65.00% > 18% (prev 0.62%; Δ 6439 % > 0.5%) |
| Asset Turnover: 128.1% > 50% (prev 92.14%; Δ 35.99% > 0%) |
| Interest Coverage Ratio: 7.71 > 6 (EBITDA TTM 6.07b / Interest Expense TTM 568.5m) |
Altman Z'' 1.09
| A: -0.21 (Total Current Assets 2.95b - Total Current Liabilities 5.98b) / Total Assets 14.73b |
| B: 0.13 (Retained Earnings 1.89b / Total Assets 14.73b) |
| C: 0.30 (EBIT TTM 4.38b / Avg Total Assets 14.82b) |
| D: 0.03 (Book Value of Equity 392.3m / Total Liabilities 12.35b) |
| Altman-Z'' Score: 1.09 = BB |
Beneish M -3.10
| DSRI: 0.77 (Receivables 2.46b/2.32b, Revenue 18.99b/13.74b) |
| GMI: 0.95 (GM 65.00% / 61.53%) |
| AQI: 0.99 (AQ_t 0.79 / AQ_t-1 0.79) |
| SGI: 1.38 (Revenue 18.99b / 13.74b) |
| TATA: -0.10 (NI 3.99b - CFO 5.51b) / TA 14.73b) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of RELX shares?
As of March 11, 2026, the stock is trading at USD 35.19 with a total of 3,978,204 shares traded.
Over the past week, the price has changed by +0.72%, over one month by +20.14%, over three months by -12.20% and over the past year by -24.45%.
Over the past week, the price has changed by +0.72%, over one month by +20.14%, over three months by -12.20% and over the past year by -24.45%.
Is RELX a buy, sell or hold?
Relx has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy RELX.
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RELX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 51.5 | 46.3% |
| Analysts Target Price | 51.5 | 46.3% |
RELX Fundamental Data Overview March 10, 2026
P/E Trailing = 23.9463
P/E Forward = 18.6916
P/S = 6.6916
P/B = 20.3073
P/EG = 1.437
Revenue TTM = 18.99b USD
EBIT TTM = 4.38b USD
EBITDA TTM = 6.07b USD
Long Term Debt = 5.53b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.57b USD (from shortTermDebt, last quarter)
Debt = 7.32b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.19b USD (from netDebt column, last quarter)
Enterprise Value = 71.36b USD (64.17b + Debt 7.32b - CCE 130.8m)
Interest Coverage Ratio = 7.71 (Ebit TTM 4.38b / Interest Expense TTM 568.5m)
EV/FCF = 13.05x (Enterprise Value 71.36b / FCF TTM 5.47b)
FCF Yield = 7.67% (FCF TTM 5.47b / Enterprise Value 71.36b)
FCF Margin = 28.80% (FCF TTM 5.47b / Revenue TTM 18.99b)
Net Margin = 21.02% (Net Income TTM 3.99b / Revenue TTM 18.99b)
Gross Margin = 65.00% ((Revenue TTM 18.99b - Cost of Revenue TTM 6.65b) / Revenue TTM)
Gross Margin QoQ = 63.75% (prev 66.25%)
Tobins Q-Ratio = 4.84 (Enterprise Value 71.36b / Total Assets 14.73b)
Interest Expense / Debt = 1.07% (Interest Expense 78.5m / Debt 7.32b)
Taxrate = 25.09% (365.7m / 1.46b)
NOPAT = 3.28b (EBIT 4.38b * (1 - 25.09%))
Current Ratio = 0.49 (Total Current Assets 2.95b / Total Current Liabilities 5.98b)
Debt / Equity = 3.10 (Debt 7.32b / totalStockholderEquity, last quarter 2.36b)
Debt / EBITDA = 1.18 (Net Debt 7.19b / EBITDA 6.07b)
Debt / FCF = 1.31 (Net Debt 7.19b / FCF TTM 5.47b)
Total Stockholder Equity = 2.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 26.93% (Net Income 3.99b / Total Assets 14.73b)
RoE = 142.1% (Net Income TTM 3.99b / Total Stockholder Equity 2.81b)
RoCE = 52.54% (EBIT 4.38b / Capital Employed (Equity 2.81b + L.T.Debt 5.53b))
RoIC = 33.27% (NOPAT 3.28b / Invested Capital 9.86b)
WACC = 7.03% (E(64.17b)/V(71.49b) * Re(7.74%) + D(7.32b)/V(71.49b) * Rd(1.07%) * (1-Tc(0.25)))
Discount Rate = 7.74% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.67%
[DCF] Terminal Value 84.49% ; FCFF base≈4.51b ; Y1≈5.56b ; Y5≈9.48b
[DCF] Fair Price = 106.7 (EV 199.01b - Net Debt 7.19b = Equity 191.82b / Shares 1.80b; r=7.03% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 38.20 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.04 | Revenue CAGR: 16.86% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.94 | Chg7d=-0.016 | Chg30d=+0.020 | Revisions Net=+1 | Growth EPS=+11.4% | Growth Revenue=+5.9%
EPS next Year (2027-12-31): EPS=2.17 | Chg7d=-0.027 | Chg30d=+0.083 | Revisions Net=+2 | Growth EPS=+12.0% | Growth Revenue=+6.4%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.8% (Discount Rate 7.9% - Earnings Yield 4.2%)
[Growth] Growth Spread = +2.6% (Analyst 6.4% - Implied 3.8%)
P/E Forward = 18.6916
P/S = 6.6916
P/B = 20.3073
P/EG = 1.437
Revenue TTM = 18.99b USD
EBIT TTM = 4.38b USD
EBITDA TTM = 6.07b USD
Long Term Debt = 5.53b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.57b USD (from shortTermDebt, last quarter)
Debt = 7.32b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.19b USD (from netDebt column, last quarter)
Enterprise Value = 71.36b USD (64.17b + Debt 7.32b - CCE 130.8m)
Interest Coverage Ratio = 7.71 (Ebit TTM 4.38b / Interest Expense TTM 568.5m)
EV/FCF = 13.05x (Enterprise Value 71.36b / FCF TTM 5.47b)
FCF Yield = 7.67% (FCF TTM 5.47b / Enterprise Value 71.36b)
FCF Margin = 28.80% (FCF TTM 5.47b / Revenue TTM 18.99b)
Net Margin = 21.02% (Net Income TTM 3.99b / Revenue TTM 18.99b)
Gross Margin = 65.00% ((Revenue TTM 18.99b - Cost of Revenue TTM 6.65b) / Revenue TTM)
Gross Margin QoQ = 63.75% (prev 66.25%)
Tobins Q-Ratio = 4.84 (Enterprise Value 71.36b / Total Assets 14.73b)
Interest Expense / Debt = 1.07% (Interest Expense 78.5m / Debt 7.32b)
Taxrate = 25.09% (365.7m / 1.46b)
NOPAT = 3.28b (EBIT 4.38b * (1 - 25.09%))
Current Ratio = 0.49 (Total Current Assets 2.95b / Total Current Liabilities 5.98b)
Debt / Equity = 3.10 (Debt 7.32b / totalStockholderEquity, last quarter 2.36b)
Debt / EBITDA = 1.18 (Net Debt 7.19b / EBITDA 6.07b)
Debt / FCF = 1.31 (Net Debt 7.19b / FCF TTM 5.47b)
Total Stockholder Equity = 2.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 26.93% (Net Income 3.99b / Total Assets 14.73b)
RoE = 142.1% (Net Income TTM 3.99b / Total Stockholder Equity 2.81b)
RoCE = 52.54% (EBIT 4.38b / Capital Employed (Equity 2.81b + L.T.Debt 5.53b))
RoIC = 33.27% (NOPAT 3.28b / Invested Capital 9.86b)
WACC = 7.03% (E(64.17b)/V(71.49b) * Re(7.74%) + D(7.32b)/V(71.49b) * Rd(1.07%) * (1-Tc(0.25)))
Discount Rate = 7.74% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.67%
[DCF] Terminal Value 84.49% ; FCFF base≈4.51b ; Y1≈5.56b ; Y5≈9.48b
[DCF] Fair Price = 106.7 (EV 199.01b - Net Debt 7.19b = Equity 191.82b / Shares 1.80b; r=7.03% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 38.20 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.04 | Revenue CAGR: 16.86% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.94 | Chg7d=-0.016 | Chg30d=+0.020 | Revisions Net=+1 | Growth EPS=+11.4% | Growth Revenue=+5.9%
EPS next Year (2027-12-31): EPS=2.17 | Chg7d=-0.027 | Chg30d=+0.083 | Revisions Net=+2 | Growth EPS=+12.0% | Growth Revenue=+6.4%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.8% (Discount Rate 7.9% - Earnings Yield 4.2%)
[Growth] Growth Spread = +2.6% (Analyst 6.4% - Implied 3.8%)